Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-01-22
2000-03-21
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546187, 546191, A61K 31445, C07D40106
Patent
active
060403160
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Over the last decade, major advances have been made in the understanding of the biology of the mammalian tachykinin neuropeptides. It is now well established that substance-P (1), neurokinin A (NKA) (2), and neurokinin B (NKB) (3), all of which share a common C-terminal sequence Phe-X-Gly-Leu-Met-NH.sub.2, (Nakanishi S., Physiol. Rev., 1987;67:117), are widely distributed throughout the periphery and central nervous system (CNS) where they appear to interact with at least three receptor types referred to as NK.sub.1, NK.sub.2, and NK.sub.3, (Guard S., et al., Neurosci. Int., 1991;18:149). Substance-P displays highest affinity for NK.sub.1 receptors, whereas NKA and NKB bind preferentially to NK.sub.2 and NK.sub.3 receptors, respectively. Recently, all three receptors have been clones and sequenced and shown to be members of the G-protein-linked "super family" of receptors (Nakanishi S., Annu. Rev. Neurosci., 1991;14:123). A wealth of evidence supports the involvement of tachykinin neuropeptides in a variety of biological activities including pain transmission, vasodilation, smooth muscle contraction, bronchoconstriction, activation of the immune system (inflammatory pain), and neurogenic inflammation (Pernow B., Pharmacol. Rev., 1983;35:85). However, to date, a detailed understanding of the physiological roles of tachykinin neuropeptides has been severely hampered by a lack of selective, high affinity, metabolically stable tachykinin receptor antagonists that possess both good bioavailability and CNS penetration. Although several tachykinin receptor antagonists have been described (Tomszuk B. E., et al., Current Opinions in Therapeutic Patents, 1991;1:197), most have been developed through the modification and/or deletion of one or more of the amino acids that comprise the endogenous mammalian tachykinins such that the resulting molecules are still peptides that possess poor pharmacokinetic properties and limited in vivo activities.
However, since 1991, a number of high-affinity nonpeptide antagonists have been reported. Snider R. M., et al., (Science, 1991;251:435), and Garret C., et al., (Proc. Natl. Acad. Sci., 1991;88:10208), described CP-96,345 and RP 67580, respectively, as antagonists at the NK.sub.1 receptor, while Advenier C., et al., (Brit. J. Pharmacol., 1992;105:78), presented data on SR 48968 showing its high affinity and selectivity for NK.sub.2 receptors. More recently Macleod, et al., (J. Med. Chem., 1993;36:2044) have published on a novel series of tryptophan derivatives as NK.sub.1 receptor antagonists. It is of interest that most of the nonpeptide tachykinin receptor antagonists described to date arose, either directly or indirectly, out of the screening of large compound collections using a robust radioligand binding assay as the primary screen. Recently, FK 888, a "dipeptide" with high affinity for the NK.sub.1 receptor was described (Fujii J., et al., Neuropeptide, 1992;22:24). Only one NK.sub.3 receptor selective ligand, SR 142801, has been published on to date (Edmonds-Alt, et al., Life Sciences, 1995;56:27).
International Publication Numbers WO 93/01169, WO 93/01165, and WO 93/001160 cover certain nonpeptide tachykinin receptor antagonists.
NKB and also NK.sub.3 receptors are distributed throughout the periphery and central nervous system (Maggi, et al., J. Auton. Pharmacol., 1993;13:23). NKB is believed to mediate a variety of biological actions via the NK.sub.3 receptor including gastric acid secretion; appetite regulation; modulation of serotonergic, cholinergic, and dopaminergic systems; smooth muscle contraction and neuronal excitation. Recent publications descriptive of this art include Polidor, et al., Neuroscience Letts., 1989;103:320; Massi, et al., Neuroscience Letts., 1988;92:341, and Improta, et al., Peptides, 1991;12:1433. Due to its actions with dopaminergic (Elliott, et al., Neuropeptides, 1991;19:119), cholinergic (Stoessl, et al., Psycho. Pharmacol., 1988;95:502), and serotonergic (Stoessl, et al., Neuroscience Letts., 1987;80:321) syst
REFERENCES:
patent: 5340822 (1994-08-01), Emonds-Alt et al.
patent: 5444074 (1995-08-01), Baker et al.
patent: 5554763 (1996-09-01), Emonds-Alt et al.
patent: 5625060 (1997-04-01), Emonds-Alt et al.
patent: 5679693 (1997-10-01), Emonds-Alt et al.
patent: 5741910 (1998-04-01), Bichon et al.
PCT International Search Report, PCT/US97/15443.
Chemical Abstracts, vol. 126, No. 21, 1997, abstract No. 277367q.
H. Chen, et al., "A Practical and Scalable Synthesis of SR 142801, A Tachykinin NK3 Antagonist", Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 5, pp. 555-560, 1997.
F.-Z. Chung, et al., "Two Classes of Structurally Different Antagonists Display Similar Species Preference for the Human Tachykinin Neurokinin.sub.3 Receptor", Molecular Pharmacology, vol. 48, pp. 711-716, 1995.
R. Patacchini, et al., "Activity of SR 142801 at peripheral tachykinin receptors", European Journal of Pharmacology, vol. 278, pp. 17-25, 1995.
Y. Tian, et al., "The Unpredicted High Affinities of a Large Number of Naturally Occurring Tachykinins for Chimeric NK.sub.1 /NK.sub.3 Receptors Suggest a Role for an Inhibitory Domain in Determining Receptor Specificity", The Journal of Biological Chemistry, vol. 271, No. 34, pp. 20250-20257, 1996.
ND Lalwani, et al., "Characterization of tachykinin-mediated calcium mobilisation in CHO-KI cells expressing human NK3 receptor", Cellular Pharmacology, vol. 2, pp. 141-146, 1995.
Y. Tian, et al., "Structural Motifs Encoded by Individual Exons of the Human Neurokinin-1 Receptor Gene Interact Differentially with Selective Agonists and Antagonists", Journal of Neurochemistry, vol. 67, No. 2, pp. 001-009, 1996.
S. Nakanishi, "Substance P Precursor and Kininogen: Their Structures, Gene Organization, and Regulation", Physiological Reviews, vol. 67, No. 4, pp. 1117-1142, 1987.
S. Guard and S. Watson, "Tachykinin Receptor Types: Classification and Membrane Signalling Mechanisms", Neurochem. Int., vol. 18, No. 2, pp. 149-165, 1991.
S. Nakanishi, "Mammalian Tachykinin Receptors", Annu. Rev. Neurosci., vol. 14, pp. 123-136, 1991.
B. Pernow, "Substance P", Pharmacology Reviews, vol. 35, No. 2, pp. 86-141, 1983.
R. Snider, et al., "A Potent Nonpeptide Antagonist of the Substance P (NK.sub.1) Receptor", Science, vol. 251, pp. 435-437, 1991.
C. Garret, et al., Pharmacological properties of a potent and selective nonpeptide substance P antagonist, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 10208-10212, 1991.
C. Advenier, et al., "Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig", Br. J. Pharmacol., vol. 105, pp. 792-798, 1992.
A. MacLeod, et al., "N-Acyl-L-tryptophan Benzyl Esters: Potent Substance P Receptor Antagonists", J. Med. Chem., vol. 36, pp. 2044-2045, 1993.
T. Fujii, et al., "Effect of Novel Substance P Antagonist, FK888, on Airway Constriction and Airway Edema in Guinea-Pigs", Neuropeptides, p. 24, 1992.
X. Emonds-Alt, et al., "SR 142801, The First Potent N-peptide Antagonist of the Tachykinin NK.sub.3 Receptor", Life Sciences, vol. 56, No. 1, pp. PL 27-32, 1995.
C. Maggi, et al., "Tachykinin receptors and tachykinin receptor antagonists", J. Auton. Pharmacol., vol. 13, pp. 23-93, 1993.
C. Polidori, et al., "Vasopressin release induced by intracranial injection of tachykinins is due to activation of central neurokinin-3 receptors", Neuroscience Letters, vol. 103, pp. 320-325, 1989.
M. Massi, et al., "The tachykinin NH.sub.2 -senktide, a selective neurokinin B receptor agonist, is a very potent inhibitor of salt appetite in the rat", Neuroscience Letters, vol. 92, pp. 341-346, 1988.
G. Improta and M. Broccardo, "Inhibitory Role on Gastric Secretion of a Central NK-3 Tachykinin Receptor Agonist, Senktide", Peptides, vol. 12, pp. 1433-1434, 1991.
P. Elliott, et al., "Behavioural and Biochemical Responses Following Activation of Midbrain Dopamine Pathways by Receptor Selective Neurokinin Agonists", Neuropeptides, vol. 19, pp. 119-126, 1991.
A. Stoessl, et al., "The NK-3 tachykinin agonist senk
Chen Michael Huai Gu
Chung Fu-Zon
Lee Helen Tsenwhei
Anderson Elizabeth M.
Chang Ceila
Warner-Lambert & Company
LandOfFree
3-alkyl-3-phenyl-piperidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-alkyl-3-phenyl-piperidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-alkyl-3-phenyl-piperidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-730577